Patents Assigned to Guangzhou Cellprotek Pharmaceutical Co., Ltd.
-
Patent number: 11911396Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.Type: GrantFiled: December 28, 2018Date of Patent: February 27, 2024Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei Yan, Wei Yin, Longxiang Sheng, Bingzheng Lu, Yijun Huang, Suizhen Lin
-
Publication number: 20230167195Abstract: Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.Type: ApplicationFiled: January 11, 2023Publication date: June 1, 2023Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei YAN, Wei YIN, Yuan LI, Bingzheng LU, Longxiang SHENG
-
Publication number: 20230089123Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pulmonary disease in a patient. These compounds can significantly inhibit the up-regulation of PFKFB3 expression, significantly inhibit the accumulation of lactate, significantly reduce vascular endothelial cell injury, significantly reduce alveolar epithelial cell injury, significantly inhibit alveolar septum thickening, significantly reduce alveolar damage, and thus can be used to treat diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury, such as in the lung.Type: ApplicationFiled: February 26, 2021Publication date: March 23, 2023Applicant: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Bingzheng Lu, Yupin Chen, Yana Wang, Jiayu Huang, Chunhui Huang, Jiesi Chen
-
Patent number: 11584802Abstract: Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.Type: GrantFiled: February 6, 2018Date of Patent: February 21, 2023Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Guangmei Yan, Wei Yin, Yuan Li, Bingzheng Lu, Longxiang Sheng
-
Patent number: 11382921Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.Type: GrantFiled: December 28, 2018Date of Patent: July 12, 2022Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei Yan, Yijun Huang, Wei Yin, Suizhen Lin
-
Publication number: 20210060035Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.Type: ApplicationFiled: December 28, 2018Publication date: March 4, 2021Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei YAN, Yijun HUANG, Wei YIN, Suizhen LIN
-
Publication number: 20200392250Abstract: Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.Type: ApplicationFiled: February 6, 2018Publication date: December 17, 2020Applicant: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Guangmei YAN, Wei YIN, Yuan LI, Bingzheng LU, Longxiang SHENG
-
Patent number: 10835539Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.Type: GrantFiled: March 25, 2019Date of Patent: November 17, 2020Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
-
Publication number: 20200330483Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.Type: ApplicationFiled: December 28, 2018Publication date: October 22, 2020Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei YAN, Wei YIN, Longxiang SHENG, Bingzheng LU, Yijun HUANG, Suizhen LIN
-
Patent number: 10357500Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.Type: GrantFiled: April 14, 2015Date of Patent: July 23, 2019Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
-
Patent number: 9944673Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.Type: GrantFiled: May 8, 2017Date of Patent: April 17, 2018Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
-
Patent number: 9944672Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.Type: GrantFiled: May 8, 2017Date of Patent: April 17, 2018Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
-
Patent number: 9688716Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.Type: GrantFiled: April 11, 2012Date of Patent: June 27, 2017Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
-
Patent number: 9428539Abstract: The present invention discloses compound 2?,3?,5?-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.Type: GrantFiled: March 28, 2014Date of Patent: August 30, 2016Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Jingxia Zhang, Suizhen Lin, Minyu Xie